Graham Capital Management, L.P. Supernus Pharmaceuticals, Inc. Transaction History
Graham Capital Management, L.P.
- $5.08 Billion
- Q4 2024
A detailed history of Graham Capital Management, L.P. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 6,908 shares of SUPN stock, worth $270,171. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,908Holding current value
$270,171% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
302Shares Held
60.6MCall Options Held
25.2KPut Options Held
2.6K-
Black Rock Inc. New York, NY10.4MShares$406 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$241 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$189 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$113 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$103 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.09B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...